Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

Science 329 (5988): 154-155

Copyright © 2010 by the American Association for the Advancement of Science

Medicine

Clearing Conformational Disease

Richard N. Sifers

Research focused on defining the underlying characteristics of a disease can often lead to new treatment strategies. This is certainly the case for a rapidly expanding group of inherited diseases characterized by the toxic accumulation of a misfolded protein (1). Identifying, and then targeting, the cellular machinery responsible for orchestrating the degradation of these aberrant molecules, rather than correcting the mutations that cause them, represents a paradigm shift from the conventional wisdom associated with gene therapy. On page 229 of this issue, Hidvegi et al. (2) describe how a compound that stimulates autophagy—the process by which a cell destroys its own organelles through lysosomal compartments—can successfully eliminate the toxic effects of misfolded {alpha}1-antitrypsin protein in a preclinical mouse model of the associated liver disease (3).

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.

E-mail: rsifers{at}bcm.edu


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Histone Deacetylase Inhibitor (HDACi) Suberoylanilide Hydroxamic Acid (SAHA)-mediated Correction of {alpha}1-Antitrypsin Deficiency.
M. Bouchecareilh, D. M. Hutt, P. Szajner, T. R. Flotte, and W. E. Balch (2012)
J. Biol. Chem. 287, 38265-38278
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882